Ciba Corning Diagnostics
This article was originally published in The Gray Sheet
Launches ACS prostate-specific antigen test for prostate cancer management Sept. 22. FDA approved the firm's premarket approval application for the test Aug. 23. The direct chemiluminescent immunoassay will be sold in the U.S. by 130 direct sales reps at a list price of $3,780 for a kit of 300 tests. Ciba Corning joins Hybritech, Tosoh Medics, and Abbott in marketing a PSA test in the U.S. The company plans to file additional data with FDA to support use of the assay to aid in the diagnosis of prostate cancer. Hybritech's Tandem recently became the first PSA test to gain FDA approval as a diagnostic aid ("The Gray Sheet" Sept. 5, p. 13)
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.